Funakoshi, Y., Hata, N., Takigawa, K., Arita, H., Kuga, D., Hatae, R., . . . Mizoguchi, M. (2021). Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma. Cancer Med.
Chicago Style citaatFunakoshi, Yusuke, et al. "Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH‐wildtype Glioblastoma." Cancer Med 2021.
MLA citatieFunakoshi, Yusuke, et al. "Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH‐wildtype Glioblastoma." Cancer Med 2021.
Let op: Deze citaties zijn niet altijd 100% accuraat.